文献速递眼底病与葡萄膜炎

HAWK和HARRIER研究:Brolucizumab治疗新生血管性年龄相关性黄斑变性的96周3期试验结果

HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2020-06-20

HAWK和HARRIER是两项3期随机双盲多中心研究,比较brolucizumab与阿柏西普治疗新生血管性年龄相关性黄斑变性(nAMD)的96周疗效与安全性。结果显示brolucizumab在维持视力获益的同时,在减少视网膜厚度和视网膜积液方面优于阿柏西普,且q12w给药潜力维持至96周。

要点

  • Brolucizumab 6 mg在HAWK和HARRIER中减少中央亚区厚度均优于阿柏西普。
  • Brolucizumab组视网膜内液和/或视网膜下液比例低于阿柏西普组。
  • Brolucizumab 6 mg维持q12w给药的概率在HAWK为45.4%、HARRIER为38.6%。

核心结论

  • Brolucizumab 48周视力获益维持至96周,且液体消退优于阿柏西普。

研究设计与样本

  • 两项3期前瞻性随机双盲多中心研究,纳入未治疗nAMD眼,随机接受brolucizumab 3 mg(仅HAWK)、6 mg或阿柏西普2 mg。

主要发现

  • HAWK中96周BCVA平均变化:brolucizumab 3 mg为5.6±0.79字母,6 mg为5.90±0.78字母,阿柏西普为5.3±0.78字母。
  • HARRIER中96周BCVA平均变化:brolucizumab 6 mg为6.1±0.73字母,阿柏西普为6.6±0.73字母。
  • HAWK中96周中央亚区厚度降幅:brolucizumab 6 mg为-174.8 μm,阿柏西普为-148.7 μm(治疗差异95%CI -46.2至-5.9 μm,P=0.0115)。
  • HARRIER中96周中央亚区厚度降幅:brolucizumab 6 mg为-197.7 μm,阿柏西普为-155.1 μm(治疗差异95%CI -62.0至-23.3 μm,P<0.0001)。
  • 96周视网膜内液和/或视网膜下液比例:HAWK中brolucizumab 3 mg为31%(P=0.0688)、6 mg为24%(P=0.0002)、阿柏西普为37%;HARRIER中brolucizumab 6 mg为24%(P<0.0001)、阿柏西普为39%。

关键数值与推荐

  • 92周(末次疾病活动评估)时brolucizumab 6 mg维持q12w给药的概率:HAWK为45.4%,HARRIER为38.6%。

临床怎么用

  • Brolucizumab可用于nAMD治疗,在减少视网膜厚度和积液方面可能优于阿柏西普,并可能延长给药间隔至q12w。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the 96-week outcomes from HAWK and HARRIER. DESIGN: Phase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy and safety of brolucizumab 3 mg (HAWK only) and 6 mg with aflibercept 2 mg in eyes with neovascular age-related macular degeneration (nAMD). PARTICIPANTS: Treatment-naïve eyes with nAMD were randomized 1:1:1 to brolucizumab 3 mg (n = 358), brolucizumab 6 mg (n = 360), aflibercept 2 mg (n = 360; HAWK) or 1:1 to brolucizumab 6 mg (n = 370), aflibercept 2 mg (n = 369; HARRIER). METHODS: After 3 monthly loading doses, brolucizumab patients received every (q)-12-week (w) dosing, possibly adjusting to q8w dosing if disease activity was present at predefined disease activity assessment (DAA) visits. Aflibercept was dosed in a fixed q8w regimen. Visual and anatomic parameters were assessed throughout. Primary end point was at week 48 (48w), confirmed at 96w. MAIN OUTCOME MEASURES: Mean best-corrected visual acuity (BCVA) change from baseline, proportion of patients on an q12w regimen, retinal thickness, retinal fluid changes, and safety, all to 96w. RESULTS: Mean change (least squares [LS] mean ± standard error) in BCVA from baseline to 96w in HAWK was 5.6±0.79 Early Treatment Diabetic Retinopathy Study (ETDRS) letters for brolucizumab 3 mg, 5.90±0.78 letters for brolucizumab 6 mg, and 5.3±0.78 letters for aflibercept and in HARRIER was 6.1±0.73 letters for brolucizumab 6 mg and 6.6 ± 0.73 letters for aflibercept. Greater central subfield thickness reductions were observed with brolucizumab 6 mg versus aflibercept in HAWK (LS mean, -174.8 μm vs. -148.7 μm; 95% confidence interval for treatment difference, -46.2 to -5.9 μm; P = 0.0115) and HARRIER (LS mean, -197.7 μm vs. -155.1 μm; 95% confidence interval for treatment difference, -62.0 to -23.3 μm; P < 0.0001). The proportions of eyes with intraretinal fluid and/or subretinal fluid (IRF/SRF) at 96w in HAWK were 31% (P = 0.0688) and 24% (P = 0.0002) for brolucizumab 3 mg and 6 mg and 37% for aflibercept, whereas in HARRIER, they were 24% for brolucizumab 6 mg (P < 0.0001) and 39% for aflibercept. At 92w (last DAA), a 45.4% and 38.6% probability was observed for brolucizumab 6 mg patients of maintaining an q12w treatment regimen in HAWK and HARRIER, respectively. Brolucizumab exhibited an overall well-tolerated safety profile. CONCLUSIONS: Visual outcomes from 48w to 96w confirm the efficacy achieved at 48w. Brolucizumab demonstrated greater fluid resolution compared with aflibercept. The q12w potential for brolucizumab observed at 48w was maintained to 96w.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase 3 Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020. PMID: 32574761. doi:10.1016/j.ophtha.2020.06.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。